PULM Pulmatrix, Inc.
Pulmatrix, Inc. (PULM) is expected to report earnings on November 12, 2026, before the market open.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Pulmatrix, Inc.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for serious lung diseases such as allergic bronchopulmonary aspergillosis ("ABPA") and lung cancer, as well as neurologic disorders such as acute migraine.
Sector
Healthcare
Industry
Biotechnology